{ "company": "IQVIA Holdings", "ticker": "IQV", "period": { "from": "2026-03-15", "to": "2026-04-14", "days": 30 }, "sentiment_breakdown": { "positive": 26, "negative": 6, "neutral": 23 }, "synthesis": { "executive_summary": "Sentiment analysis for IQVIA Holdings (IQV) from 2026-03-15 to 2026-04-14. Analyzed 55 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution", "date": "2026-03-31", "source": "alpha_vantage", "score": 0.991 }, { "title": "$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics", "date": "2026-04-09", "source": "news", "score": 0.943 }, { "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "date": "2026-04-13", "source": "alpha_vantage", "score": 0.711 }, { "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "date": "2026-04-01", "source": "alpha_vantage", "score": 0.711 }, { "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "date": "2026-03-30", "source": "alpha_vantage", "score": 0.711 }, { "title": "Charles River Labs stock: Margin Boost from Divestitures Signals Buy Opportunity", "date": "2026-04-10", "source": "alpha_vantage", "score": 0.67 }, { "title": "Wealth Enhancement Advisory Services LLC Purchases 9,480 Shares of IQVIA Holdings Inc. $IQV", "date": "2026-03-28", "source": "alpha_vantage", "score": 0.66 }, { "title": "Healthcare: Increased Clarity on Drug Pricing and Tariffs Led to a Rebound in Q1", "date": "2026-04-01", "source": "alpha_vantage", "score": 0.586 }, { "title": "Patient Derived Xenograft (PDX) Models Market is estimated to Hit US$ 19.46 billion by 2032 | Major Companies - Charles River Laboratories, Champions Oncology, Inc., EPO Berlin-Buch GmbH", "date": "2026-04-09", "source": "alpha_vantage", "score": 0.527 }, { "title": "SG Americas Securities LLC Buys 26,161 Shares of IQVIA Holdings Inc. $IQV", "date": "2026-03-30", "source": "alpha_vantage", "score": 0.527 } ], "top_negative": [ { "title": "AI-led selloff in contract research firms may be misjudging disruption risk", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.557 }, { "title": "Evercore Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $185", "date": "2026-04-08", "source": "alpha_vantage", "score": -0.296 }, { "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors", "date": "2026-04-09", "source": "alpha_vantage", "score": -0.2 }, { "title": "IQVIA Holdings Inc. stock rises Wednesday, still underperforms market", "date": "2026-04-08", "source": "alpha_vantage", "score": -0.2 }, { "title": "IQVIA Holdings Inc. stock underperforms Monday when compared to competitors", "date": "2026-04-06", "source": "alpha_vantage", "score": -0.2 }, { "title": "IQVIA Holdings Inc. stock rises Tuesday, still underperforms market", "date": "2026-03-31", "source": "alpha_vantage", "score": -0.2 } ], "raw_data": { "total_items": 55, "items": [ { "source": "news", "source_name": "GlobeNewswire", "title": "$1.05 Bn Biopharmaceutical CXO Markets - Global Forecast Report 2026-2032: How Leading Pharmas Such as Pfizer, Roche, Novartis, Sanofi, and AstraZeneca Navigate the Evolving Dynamics", "description": "The biopharmaceutical CXO market offers opportunities in strategic outsourcing, digital integration, resilient supply chains, and value-driven partnerships amidst evolving regulatory landscapes. The biopharmaceutical CXO market offers opportunities in strateg…", "url": "https://www.globenewswire.com/news-release/2026/04/09/3270735/28124/en/1-05-Bn-Biopharmaceutical-CXO-Markets-Global-Forecast-Report-2026-2032-How-Leading-Pharmas-Such-as-Pfizer-Roche-Novartis-Sanofi-and-AstraZeneca-Navigate-the-Evolving-Dynamics.html", "date": "2026-04-09", "published_at": "2026-04-09T10:05:00Z", "sentiment": { "label": "positive", "score": 0.943, "confidence": 0.94 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "IQVIA Holdings Inc. (IQV): Billionaire David Tepper Makes Minor Adjustment", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_aca927a4-f5a6-41e8-a121-330b5bf66fde", "date": "2026-04-07", "published_at": "2026-04-07T14:28:03Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Dermatomyositis Global Clinical Trials Market Review Report 2026: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status", "description": "The clinical trial report highlights opportunities in Dermatomyositis trials by revealing key trends in trial phases, sponsor types, and regions, particularly in G7 and E7 countries. It aids strategic decision-making by identifying prime trial locations and o…", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269299/28124/en/Dermatomyositis-Global-Clinical-Trials-Market-Review-Report-2026-Region-Country-G7-E7-Trial-Status-Trial-Phase-Sponsor-Type-and-End-Point-Status.html", "date": "2026-04-07", "published_at": "2026-04-07T13:28:00Z", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_14b688ee-99d8-45eb-830b-c9df2dca0d5d", "date": "2026-04-05", "published_at": "2026-04-05T18:31:21Z", "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "TD Cowen Upgrades IQVIA (IQV) to Buy and Raises Price Target to $213", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_0f826ad2-de99-47c1-afef-222a2c734ee3", "date": "2026-03-24", "published_at": "2026-03-24T14:43:11Z", "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-a7a29e63-ac973e3e4ede", "date": "2026-04-13", "summary": "Shares of IQVIA Holdings Inc. (IQV) rose by 2.78% to $171.99 on Monday, outperforming the broader market. This strong performance ended a two-day losing streak for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw gains on what was a positive trading day.", "sentiment_score": 0.431926, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "ICON plc stock (IE0005711209): Is clinical trial demand strong enough to drive U.S. investor upside?", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/icon-plc-stock-ie0005711209-is-clinical-trial-demand-strong-enough-to/69137214", "date": "2026-04-13", "summary": "ICON plc, a leading contract research organization (CRO), plays a crucial role in drug development by managing clinical trials for pharmaceutical, biotech, and medical device companies globally, with significant U.S. operations. The company's business model offers stable revenue streams by outsourcing trial management, reducing costs and timelines for sponsors, and positioning it as an attractive investment for U.S. investors seeking exposure to the pharmaceutical market without direct biotech r", "sentiment_score": 0.232926, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.62886, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley", "url": "https://finance.yahoo.com/markets/stocks/articles/vertex-pharmaceuticals-price-target-raised-125847886.html", "date": "2026-04-11", "summary": "Morgan Stanley has increased its price target for Vertex Pharmaceuticals (VRTX) to $612 from $596, maintaining an Overweight rating on the shares. This adjustment reflects updated models based on IQVIA trends and intra-quarter updates in anticipation of Q1 earnings reports from biopharma companies.", "sentiment_score": 0.116163, "sentiment_label": "Neutral", "relevance_score": 0.64298, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Soars to Top Trading Volume With $240 Million Transaction Ahead of Earnings Release", "url": "https://www.bitget.com/amp/news/detail/12560605357862", "date": "2026-04-11", "summary": "IQVIA Holdings Inc. (IQV) experienced a significant trading volume of $240 million on April 10, 2026, despite a slight share price decrease, placing it at the top of daily trading volume rankings ahead of its earnings release on April 23, 2026. The company demonstrated strong Q4 2025 performance, surpassing revenue and EPS expectations, driven by AI initiatives and acquisitions, yet faces market challenges including economic pressures and competition. Technical analysis indicates a bearish trend", "sentiment_score": -0.227457, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Discipline and Rules-Based Execution in IQV Response", "url": "https://news.stocktradersdaily.com/news_release/90/Discipline_and_Rules-Based_Execution_in_IQV_Response_041026090001_1775869201.html", "date": "2026-04-10", "summary": "This article provides an AI-generated analysis of Iqvia Holdings Inc. (NYSE: IQV), indicating a neutral near and mid-term outlook with a potential long-term positive bias but elevated downside risk. It offers three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors.", "sentiment_score": 0.019264, "sentiment_label": "Neutral", "relevance_score": 0.320176, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Here’s Why Keeping IQV Stock in Your Portfolio Makes Sense Right Now", "url": "https://www.bitget.com/amp/news/detail/12560605356296", "date": "2026-04-10", "summary": "IQVIA Holdings (IQV) has shown strong share price growth, outperforming its industry, driven by its integration of AI into life sciences, commitment to sustainability, strategic acquisitions, and shareholder value initiatives. Despite these strengths, the company faces liquidity challenges with a declining current ratio. While IQV holds a \"Hold\" rank, alternative strong buy options like Dave Inc. (DAVE) and Maximus (MMS) are noted for investors.", "sentiment_score": 0.444522, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Here's Why You Should Retain IQV Stock in Your Portfolio Now", "url": "https://www.tradingview.com/news/zacks:d51e60dc9094b:0-here-s-why-you-should-retain-iqv-stock-in-your-portfolio-now/", "date": "2026-04-10", "summary": "IQVIA Holdings (IQV) has outperformed its industry over the past year and shows strong long-term EPS growth potential, driven by strategic AI integration (IQVIA.ai with NVIDIA), a commitment to sustainability, and proactive acquisitions. Despite these positive factors, the company faces significant challenges due to weak liquidity, as indicated by a consistently falling current ratio. IQVIA maintains a Zacks Rank of #3 (Hold), while other recommended stocks like Dave Inc. (DAVE) and Maximus (MMS", "sentiment_score": 0.610355, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Soars to Top Trading Volume With $240 Million Transaction Ahead of Earnings Release", "url": "https://www.bitget.com/news/detail/12560605357862", "date": "2026-04-10", "summary": "IQVIA Holdings Inc (IQV) experienced strong investor interest with $240 million in trading volume, a 24.37% increase, despite a slight 0.97% share price decrease on April 10, 2026, ahead of its earnings announcement on April 23. This surge in volume pushed IQVIA to the top of daily trading rankings. The company has shown solid operational results, outperforming Q4 2025 analyst projections, but faces market caution due to broader economic pressures, integration challenges, and increased competiti", "sentiment_score": -0.27695, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Charles River Labs stock: Margin Boost from Divestitures Signals Buy Opportunity", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/charles-river-labs-stock-margin-boost-from-divestitures-signals-buy/69116787", "date": "2026-04-10", "summary": "Charles River Labs is strategically divesting low-margin units to focus on high-growth diagnostics, significantly boosting operating margins by at least 100 basis points and raising its 2026 EPS guidance. This pivot positions CRL as an attractive investment in the biopharma services sector, appealing to investors looking for resilient companies amid stabilizing demand and emphasizing profitability over top-line growth. Analysts maintain a \"Buy\" consensus, with a median price target of $202, sign", "sentiment_score": -0.100537, "sentiment_label": "Neutral", "relevance_score": 0.637777, "sentiment": { "label": "positive", "score": 0.67, "confidence": 0.67 } }, { "source": "alpha_vantage", "title": "Here’s Why Keeping IQV Stock in Your Portfolio Makes Sense Right Now", "url": "https://www.bitget.com/news/detail/12560605356296", "date": "2026-04-09", "summary": "IQVIA Holdings (IQV) has shown strong growth, with its share price increasing by 22.6% over the past year, driven by strategic AI integration, sustainability efforts, and key acquisitions. The company projects a long-term EPS growth rate of 13% and has an active share buyback program. However, IQVIA faces liquidity challenges with a declining current ratio, and currently holds a Zacks Rank of #3 (Hold), with alternative higher-ranked stock picks including Dave Inc. (DAVE) and Maximus (MMS).", "sentiment_score": 0.405715, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQV Technical Analysis & Stock Price Forecast", "url": "https://intellectia.ai/en/stock/IQV/technical", "date": "2026-04-09", "summary": "This article provides a technical analysis of IQVIA Holdings Inc (IQV), indicating a \"Strong Sell\" consensus based on various technical signals. It details momentum indicators like RSI and MACD, support and resistance levels, and analyzes its performance relative to several moving averages. The analysis concludes that IQV is currently exhibiting a \"Strong Sell\" sentiment, with its stock price at $168.98, trading below its 60-day and 200-day moving averages.", "sentiment_score": -0.446823, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc (IQV) Trading Down 3.39% on Apr 9", "url": "https://www.gurufocus.com/news/8785432/iqvia-holdings-inc-iqv-trading-down-339-on-apr-9?mobile=true", "date": "2026-04-09", "summary": "IQVIA Holdings Inc (IQV) shares dropped 3.39% on April 9th, trading at $166.69. Despite the intraday dip, analysts forecast an average target price of $234.30, suggesting a potential upside of 40.56%. GuruFocus estimates an even higher fair value of $264.33, indicating a 58.58% upside.", "sentiment_score": 0.063278, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock underperforms Thursday when compared to competitors", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-thursday-when-compared-to-competitors-5e6c463c-42c5bede7f14?mod=mw_quote_news", "date": "2026-04-09", "summary": "Shares of IQVIA Holdings Inc. (IQV) fell by 2.06% on Thursday, closing at $168.98, despite a positive trading session for the broader market with the S&P 500 and Dow Jones Industrial Average both rising. The company's stock is currently trading 31.60% below its 52-week high of $247.05, which was reached on January 9th.", "sentiment_score": -0.449983, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Patient Derived Xenograft (PDX) Models Market is estimated to Hit US$ 19.46 billion by 2032 | Major Companies - Charles River Laboratories, Champions Oncology, Inc., EPO Berlin-Buch GmbH", "url": "https://www.openpr.com/news/4461718/patient-derived-xenograft-pdx-models-market-is-estimated", "date": "2026-04-09", "summary": "The Patient Derived Xenograft (PDX) Models Market is projected to reach US$ 19.46 billion by 2032, growing at a CAGR of 15% from US$ 7.2 billion in 2025. This growth is driven by the increasing use of PDX models in preclinical research for drug efficacy testing, biomarker discovery, and personalized medicine in oncology. Key players in this market include Charles River Laboratories, Champions Oncology, Inc., and EPO Berlin-Buch GmbH, with significant recent developments in AI integration, expans", "sentiment_score": -0.123398, "sentiment_label": "Neutral", "relevance_score": 0.604878, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "BLFS Stock Price, Quote & Chart | BIOLIFE SOLUTIONS INC (NASDAQ:BLFS)", "url": "https://www.chartmill.com/stock/quote/BLFS/profile", "date": "2026-04-08", "summary": "This article provides detailed stock information for BioLife Solutions Inc. (NASDAQ: BLFS), including its current stock price, performance metrics, key statistics, technical and fundamental analysis ratings from ChartMill, and insights into its latest earnings report and analyst forecasts. The company specializes in biopreservation tools for cells and tissues.", "sentiment_score": 0.100611, "sentiment_label": "Neutral", "relevance_score": 0.603736, "sentiment": { "label": "positive", "score": 0.347, "confidence": 0.35 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock rises Wednesday, still underperforms market", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-rises-wednesday-still-underperforms-market-296b76aa-ea4945bdf926?mod=mw_quote_news", "date": "2026-04-08", "summary": "Shares of IQVIA Holdings Inc. rose 1.13% on Wednesday to $172.54, breaking a two-day losing streak. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index increased by 2.51% and the Dow Jones Industrial Average grew by 2.85%.", "sentiment_score": 0.229497, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.910991, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "NTRA Financials: Revenue Breakdown, Margins & Competitor Comparison", "url": "https://intellectia.ai/en/stock/NTRA/financials", "date": "2026-04-08", "summary": "This article provides a financial analysis of Natera Inc (NTRA), detailing its revenue breakdown, profit margins, and a comparison with competitors. Natera primarily generates revenue from insurance carriers, holding a significant market share with a $29.66 billion market capitalization. It highlights the company's gross margin, operating margin, and net margin, alongside its Return on Equity, and benchmarks its gross margin against industry rivals IQV and UTHR.", "sentiment_score": 0.137372, "sentiment_label": "Neutral", "relevance_score": 0.632806, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Evercore Maintains IQVIA Holdings(IQV.US) With Buy Rating, Cuts Target Price to $185", "url": "https://www.moomoo.com/news/post/68042801/evercore-maintains-iqvia-holdings-iqvus-with-buy-rating-cuts-target", "date": "2026-04-08", "summary": "Evercore has reiterated its Buy rating on IQVIA Holdings (IQV.US) but has reduced its target price to $185. This adjustment in target price comes despite maintaining a positive outlook on the company's stock.", "sentiment_score": 0.130511, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. (IQV): Billionaire David Tepper makes minor adjustment", "url": "https://www.msn.com/en-us/money/topstocks/iqvia-holdings-inc-iqv-billionaire-david-tepper-makes-minor-adjustment/ar-AA20lBpc?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-08", "summary": "Billionaire David Tepper's Appaloosa LP recently made a minor adjustment to its holdings in IQVIA Holdings Inc. (IQV). This move involved reducing his stake by a slight margin, impacting the overall portfolio by a minimal amount. Despite this small change, IQVIA Holdings remains a significant portion of Appaloosa's portfolio.", "sentiment_score": 0.026775, "sentiment_label": "Neutral", "relevance_score": 0.346601, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Baird Adjusts Price Target on IQVIA Holdings to $230 From $243, Maintains Outperform Rating", "url": "https://www.moomoo.com/news/post/68034880/baird-adjusts-price-target-on-iqvia-holdings-to-230-from", "date": "2026-04-08", "summary": "Baird has adjusted its price target for IQVIA Holdings (IQV) to $230, down from the previous $243. Despite this reduction, the firm has chosen to maintain its \"Outperform\" rating on the company's stock. This indicates continued confidence in IQVIA's potential, even with a revised valuation.", "sentiment_score": -0.230621, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "United States Bioanalytical Testing Services Market Size,", "url": "https://www.openpr.com/news/4459769/united-states-bioanalytical-testing-services-market-size", "date": "2026-04-08", "summary": "The United States Bioanalytical Testing Services Market is projected to reach US$ 12.24 Billion by 2033, growing at a CAGR of 12.6% from 2026, driven by increased demand for complex drug development and the adoption of biologics. North America currently leads with a 40% market share. Key players like IQVIA and Labcorp are expanding capabilities to meet the rising demand fueled by R&D, clinical trials, and technological advancements in analytical methods.", "sentiment_score": 0.288151, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.870891, "sentiment": { "label": "positive", "score": 0.421, "confidence": 0.42 } }, { "source": "alpha_vantage", "title": "IQVIA.ai Launch With Nvidia Puts AI At Core Of Pharma Ties", "url": "https://www.sahmcapital.com/news/content/iqviaai-launch-with-nvidia-puts-ai-at-core-of-pharma-ties-2026-04-07", "date": "2026-04-08", "summary": "IQVIA Holdings has launched IQVIA.ai, a new AI platform developed with Nvidia, aimed at integrating healthcare-grade AI, data, and compliance for life sciences clients. The platform is already seeing adoption among several top global pharmaceutical companies, positioning IQVIA to deepen client relationships and differentiate itself in a competitive market. Investors are advised to monitor the platform's impact on contract wins, client spending, and the company's financial performance amidst pote", "sentiment_score": 0.345522, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. (IQV): Billionaire David Tepper Makes Minor Adjustment", "url": "https://www.insidermonkey.com/blog/iqvia-holdings-inc-iqv-billionaire-david-tepper-makes-minor-adjustment-1732955/", "date": "2026-04-07", "summary": "Billionaire David Tepper's Appaloosa Management LP has made a minor 1.7% reduction in its IQVIA Holdings Inc. (IQV) stake in Q4 2025, now holding 280,000 shares. This adjustment follows previous reductions since Q2 2025. The company is gaining Wall Street interest due to its IQVIA.ai platform, powered by NVIDIA, and normalization of trial cancellations, contributing to a high revenue visibility through 2027.", "sentiment_score": 0.421643, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Citi Maintains IQVIA Holdings(IQV.US) With Hold Rating, Maintains Target Price $200", "url": "https://www.moomoo.com/news/post/67971546/citi-maintains-iqvia-holdings-iqvus-with-hold-rating-maintains-target", "date": "2026-04-07", "summary": "Citi has reiterated its Hold rating on IQVIA Holdings (IQV.US), maintaining a target price of $200 for the company's shares. This action indicates Citi's continued neutral outlook on IQVIA's stock performance.", "sentiment_score": 0.021686, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock underperforms Monday when compared to competitors", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-underperforms-monday-when-compared-to-competitors-ced35bad-5f39c7d7d31b?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqdeqfhF888-Asc4pbjtoqkLJp-diZAgGQFKVQkMV27juLa9zl56GzlA&gaa_ts=69d49bb8&gaa_sig=KN5XGOGiYdKm0jPkkzjcmCZntZMZnEMximUeC12cHQ5VV2MN1Ikhq42qFYc4eE-ew3QI3SEbyJZWB6R9LpE-AQ%3D%3D", "date": "2026-04-06", "summary": "IQVIA Holdings Inc. (IQV) shares fell by 1.47% to $170.72 on Monday, despite an overall positive trading session for the stock market where the S&P 500 and Dow Jones Industrial Average both rose. This decline ended a four-day winning streak for the company's stock. The article highlights that IQVIA's performance underperformed its competitors on this specific trading day.", "sentiment_score": -0.226995, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. (IQV) stock price, news, quote and history", "url": "https://sg.finance.yahoo.com/quote/IQV/", "date": "2026-04-05", "summary": "This Yahoo Finance page provides a comprehensive overview of IQVIA Holdings Inc. (IQV) stock, including its current price, historical data, key financial metrics, and performance against benchmarks like the S&P 500. It also details the company's business segments, analyst ratings, and allows for comparison with similar companies in the Diagnostics & Research industry. The page reflects a recent stock price of $173.26 with a slight increase and notes a \"Buy\" rating upgrade from TD Cowen.", "sentiment_score": 0.149387, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia", "url": "https://www.insidermonkey.com/blog/iqvia-iqv-launches-iqvia-ai-unified-agentic-ai-platform-with-nvidia-1732342/?amp=1", "date": "2026-04-05", "summary": "IQVIA Holdings Inc. (NYSE: IQV) has launched IQVIA.ai, a unified agentic AI platform developed in collaboration with Nvidia, designed for the life sciences industry. The platform aims to enhance operational efficiency and decision-making across clinical, commercial, and real-world domains by integrating IQVIA’s healthcare-grade AI and data assets with Nvidia’s advanced technology. This system, already being adopted by top pharmaceutical companies, allows for the orchestration of tasks across mul", "sentiment_score": 0.437001, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "IQVIA (IQV) Launches IQVIA.ai Unified Agentic AI Platform with Nvidia", "url": "https://sg.finance.yahoo.com/news/iqvia-iqv-launches-iqvia-ai-183121755.html", "date": "2026-04-05", "summary": "IQVIA Holdings Inc. (IQV) has launched IQVIA.ai, a new unified agentic AI platform developed in collaboration with Nvidia, specifically designed for the life sciences industry. This platform aims to enhance operational efficiency and decision-making across clinical, commercial, and real-world domains by integrating IQVIA's healthcare-grade AI and data with Nvidia's advanced technology. Many top pharmaceutical companies have already incorporated IQVIA's agents into their workflows, and the platfo", "sentiment_score": 0.427229, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Illumina (Nasdaq:ILMN) - Stock Analysis", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina", "date": "2026-04-05", "summary": "This Simply Wall St report provides an in-depth stock analysis of Illumina (Nasdaq:ILMN), evaluating its valuation, future growth, past performance, financial health, dividends, management, and ownership. The analysis highlights that Illumina is trading below its estimated fair value, with earnings projected to grow, and the company recently became profitable. Various analyst narratives present differing views on the company's future, focusing on clinical genomics expansion, competitive challeng", "sentiment_score": 0.1306, "sentiment_label": "Neutral", "relevance_score": 0.646182, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Citigroup Maintains IQVIA Holdings (IQV) Neutral Recommendation", "url": "http://www.msn.com/en-us/money/savingandinvesting/citigroup-maintains-iqvia-holdings-iqv-neutral-recommendation/ar-AA1PtfZL?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-05", "summary": "Citigroup has reiterated its Neutral rating for IQVIA Holdings (IQV). This indicates that the analyst firm believes the stock is currently fairly valued and does not expect significant upward or downward price movements in the near future. Investors should consider this perspective when evaluating IQVIA Holdings.", "sentiment_score": 0.006508, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Aberdeen Group plc Has $43.44 Million Stake in IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-aberdeen-group-plc-has-4344-million-stake-in-iqvia-holdings-inc-iqv-2026-04-05/", "date": "2026-04-05", "summary": "Aberdeen Group plc significantly increased its stake in IQVIA Holdings Inc. by 39.6% in Q4, bringing its total holding to 192,696 shares valued at $43.44 million. Other institutional investors also adjusted their positions in the medical research company. IQVIA exceeded Q4 earnings expectations with $3.42 EPS and 10.3% year-over-year revenue growth, leading analysts to maintain an average \"Buy\" rating with an average target price of $229.13.", "sentiment_score": 0.300304, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.992423, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity, Inc. (RVTY) stock price, news, quote and history", "url": "https://uk.finance.yahoo.com/quote/RVTY/", "date": "2026-04-03", "summary": "This Yahoo Finance page provides comprehensive financial information for Revvity, Inc. (RVTY), including its current stock price, dividend announcements, historical performance data, and key metrics. It also offers an overview of the company's health sciences solutions, its market position in diagnostics and research, and analyst insights. The page enables users to compare RVTY with similar companies in the Diagnostics & Research industry.", "sentiment_score": 0.056807, "sentiment_label": "Neutral", "relevance_score": 0.640135, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "HF Advisory Group LLC Buys 146,444 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-hf-advisory-group-llc-buys-146444-shares-of-iqvia-holdings-inc-iqv-2026-04-02/", "date": "2026-04-02", "summary": "HF Advisory Group LLC significantly increased its stake in IQVIA Holdings Inc. by 1,791.6% in Q4, acquiring 146,444 shares to hold a total of 154,618 shares valued at approximately $34.85 million. This makes IQVIA the fund's 11th largest position. The medical research company currently holds a consensus \"Buy\" rating from analysts with an average price target of $229.13, and recently reported strong quarterly earnings, surpassing analyst estimates for both EPS and revenue.", "sentiment_score": 0.422396, "sentiment_label": "Bullish", "relevance_score": 0.987719, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "VNRX|VolitionRX Ltd|Price:0.200|Chg%:-0.00", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-vnrx/stock-analysis", "date": "2026-04-02", "summary": "VolitionRX Ltd (VNRX) shows weak fundamentals but high growth potential, with its revenue growing an average of 122.80% year-on-year over the past three years. The stock is considered fairly valued within its industry, despite a recent 14.25% drop and a current analyst \"Buy\" rating with upside potential of over 900%. Institutional ownership is high, though holdings decreased by 21.74% last quarter.", "sentiment_score": 0.3256, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.581896, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Healthcare: Increased Clarity on Drug Pricing and Tariffs Led to a Rebound in Q1", "url": "https://www.morningstar.com/stocks/healthcare-increased-clarity-drug-pricing-tariffs-led-rebound-q1", "date": "2026-04-01", "summary": "The Morningstar Healthcare Index, after lagging due to drug pricing uncertainty and tariffs, is expected to see solid performance in 2026, driven by its defensive nature, innovation, and benefits from AI. The sector is considered undervalued overall, with healthcare plans and devices looking most attractive. AI is anticipated to significantly reduce the time required to bring new pharmaceuticals to market, benefiting biopharma.", "sentiment_score": 0.331595, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.825698, "sentiment": { "label": "positive", "score": 0.586, "confidence": 0.59 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-50b7ce0e-58555164c769?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqf81i66v5NvTbMnPpiZ33lHKUZOEBRe4O3geGjI3IveXwUjR8KFY9ej&gaa_ts=69ce1957&gaa_sig=uF9-YbsCywYHUAA_oBPTCFHe0ojRLe4w_yvArKQ-dyARnJNFpm7CyeHZEiC0vtL-zAazv480PWqweEGa1ubkaA%3D%3D", "date": "2026-04-01", "summary": "IQVIA Holdings Inc. (IQV) stock rose 1.09% to $172.40 on Wednesday, outperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also saw gains, rising 0.72% and 0.48% respectively. This marks the third consecutive day of gains for IQVIA Holdings.", "sentiment_score": 0.449257, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. $IQV Stake Lifted by J. Safra Sarasin Holding AG", "url": "https://www.marketbeat.com/instant-alerts/filing-iqvia-holdings-inc-iqv-stake-lifted-by-j-safra-sarasin-holding-ag-2026-04-01/", "date": "2026-04-01", "summary": "J. Safra Sarasin Holding AG significantly increased its stake in IQVIA Holdings Inc. by 174.3% in the fourth quarter, now owning 12,827 shares valued at $2.89 million. Several other institutional investors also adjusted their holdings, with a large percentage of IQVIA stock owned by hedge funds. Analysts have issued varied ratings, but the company generally holds a \"Buy\" consensus with an average target price of $229.13.", "sentiment_score": 0.312859, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Positive Outlook for Narrow-Moat Iqvia Supported by Durable Demand, AI Innovation, and Execution", "url": "https://www.morningstar.com/company-reports/1463752-positive-outlook-for-narrow-moat-iqvia-supported-by-durable-demand-ai-innovation-and-execution", "date": "2026-03-31", "summary": "Iqvia, formed from the merger of Quintiles and IMS Health, is a leader in contract research organizations and life sciences data. The company benefits from durable demand, AI innovation, and strong execution. This positive outlook is supported by its strong position in real-world evidence and robust business strategy.", "sentiment_score": 0.481288, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.991, "confidence": 0.99 } }, { "source": "alpha_vantage", "title": "Progyny (NASDAQ: PGNY) schedules virtual 2026 meeting; board, audit ratification on ballot", "url": "https://www.stocktitan.net/sec-filings/PGNY/pre-14a-progyny-inc-preliminary-proxy-statement-55f7fc59e4a7.html", "date": "2026-03-31", "summary": "Progyny (NASDAQ: PGNY) has scheduled its 2026 virtual annual meeting for May 21, 2026, with a record date of March 27, 2026, and 78.3 million shares outstanding. Stockholders will vote on the election of three Class I directors, ratification of Ernst & Young LLP as the independent auditor, an advisory vote on executive compensation, and two amendments to the Certificate of Incorporation to eliminate certain supermajority voting requirements. The proposed amendments aim to streamline governance b", "sentiment_score": 0.041579, "sentiment_label": "Neutral", "relevance_score": 0.681333, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock rises Tuesday, still underperforms market", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-rises-tuesday-still-underperforms-market-7ed58b48-8be52711e922?gaa_at=eafs&gaa_n=AWEtsqdkg4GWRubztghb9qzn9GPls8JncW-HR4U_W01zwVLK23I93XDLDG-g&gaa_ts=69ccb2bd&gaa_sig=IcMs0idqDaoE01uQbOwzExZGjbPDOvwQa3Ca17tVo_6gfR9Kg6ehBx3A904friBl3eRRLJGpfcyjZIZcE5ahEw%3D%3D", "date": "2026-03-31", "summary": "IQVIA Holdings Inc. (IQV) saw its stock rise by 2.64% on Tuesday, closing at $170.54. Despite this gain, the company's performance underperformed the broader market, which experienced a favorable trading session with the S&P 500 Index and Dow Jones Industrial Average rising more significantly. This marked the second consecutive day of gains for IQVIA stock.", "sentiment_score": 0.218626, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "195,165 Shares in IQVIA Holdings Inc. $IQV Purchased by Vaughan Nelson Investment Management L.P.", "url": "https://www.marketbeat.com/instant-alerts/filing-195165-shares-in-iqvia-holdings-inc-iqv-purchased-by-vaughan-nelson-investment-management-lp-2026-03-31/", "date": "2026-03-31", "summary": "Vaughan Nelson Investment Management L.P. recently purchased 195,165 shares of IQVIA Holdings Inc. (NYSE:IQV) stock, valued at approximately $43.99 million, representing a new stake in the company. Other institutional investors have also adjusted their holdings in IQVIA. Analysts generally rate IQVIA as a \"Buy\" with a consensus price target of $229.13, following strong Q4 earnings where the company beat estimates and provided positive FY2026 guidance.", "sentiment_score": 0.477383, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "AI-led selloff in contract research firms may be misjudging disruption risk", "url": "https://www.sahmcapital.com/news/content/ai-led-selloff-in-contract-research-firms-may-be-misjudging-disruption-risk-2026-03-31", "date": "2026-03-31", "summary": "Shares of contract research organizations (CROs) have dropped due to fears that AI advancements could allow drugmakers to conduct clinical trials in-house. However, industry experts and analysts argue that the selloff overestimates AI's ability to replace CROs' core services, such as global patient recruitment and trial execution, suggesting that AI is more likely to enhance efficiency rather than disrupt the sector. While investors are concerned, analysts believe there's no evidence of pharma c", "sentiment_score": 0.245204, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.800612, "sentiment": { "label": "negative", "score": -0.557, "confidence": 0.56 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/iqvia-holdings-inc-stock-outperforms-competitors-on-strong-trading-day-09d2bbde-8f34dadb5fa6?mod=mw_quote_news&gaa_at=eafs&gaa_n=AWEtsqcwfreGoQnhWhu6rQxA27XM3I6Fh5Q6TT5gzXY2xERyhqp26ign8Q-m&gaa_ts=69cb6f3f&gaa_sig=3F9k_D6LL2qrSQRkz_tpnlCxCPM5elKjxlC1J_IbbfHeEq018I3lGg1tLkrMYLFG5b_ptBK0THlNCPDUb0Da6Q%3D%3D", "date": "2026-03-30", "summary": "Shares of IQVIA Holdings Inc. (IQV) rose 1.41% to $166.16 on Monday, outperforming the broader market. This occurred during a mixed trading session where the Dow Jones Industrial Average saw a slight increase, while the S&P 500 Index declined. The company's stock is currently 32.74% below its 52-week high.", "sentiment_score": 0.427682, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "Behavioral Patterns of IQV and Institutional Flows - Stock Traders Daily", "url": "https://news.stocktradersdaily.com/news_release/98/Behavioral_Patterns_of_IQV_and_Institutional_Flows_033026075201_1774914721.html", "date": "2026-03-30", "summary": "This article analyzes Iqvia Holdings Inc. (NYSE: IQV) using AI models to identify behavioral patterns and institutional trading flows. It suggests a weak near and mid-term sentiment, potentially challenging a long-term positive outlook, and outlines specific trading strategies (position, momentum, and risk hedging) with detailed entry, target, and stop-loss levels based on different risk profiles. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the s", "sentiment_score": -0.23727, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "IQVIA Holdings Inc (IQV) Shares Gap Down to $163.85 on Mar 30", "url": "https://www.gurufocus.com/news/8756831/iqvia-holdings-inc-iqv-shares-gap-down-to-16385-on-mar-30?mobile=true", "date": "2026-03-30", "summary": "IQVIA Holdings Inc (IQV) shares fell 3.28% in mid-day trading on March 30, reaching an intraday low of $162.36 before closing at $163.85. This puts the stock significantly below its 52-week high, while analysts maintain an \"Outperform\" rating with an average target price implying a 44.47% upside. GuruFocus' estimated fair value (GF Value) suggests an even greater potential upside of 60.57%.", "sentiment_score": -0.212435, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating", "url": "https://www.moomoo.com/news/post/67626416/truist-financial-maintains-iqvia-holdings-iqvus-with-buy-rating", "date": "2026-03-30", "summary": "Truist Financial has reaffirmed its Buy rating on IQVIA Holdings (IQV.US). This indicates a continued positive outlook from the financial institution regarding the company's stock performance.", "sentiment_score": 0.448577, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "SG Americas Securities LLC Buys 26,161 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-sg-americas-securities-llc-buys-26161-shares-of-iqvia-holdings-inc-iqv-2026-03-30/", "date": "2026-03-30", "summary": "SG Americas Securities LLC increased its stake in IQVIA Holdings Inc. by 108.8% in Q4, acquiring an additional 26,161 shares, bringing its total to 50,206 shares valued at $11.32 million. IQVIA reported strong Q4 earnings, beating analyst estimates with EPS of $3.42 and revenue of $4.36 billion, and provided positive FY2026 guidance. Wall Street analysts maintain a \"Buy\" consensus rating for IQVIA, with an average target price of $229.13.", "sentiment_score": 0.448033, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "alpha_vantage", "title": "GSK’s hepatitis B drug accepted for China regulatory review", "url": "https://www.investing.com/news/company-news/gsks-hepatitis-b-drug-accepted-for-china-regulatory-review-93CH-4586716", "date": "2026-03-30", "summary": "GSK announced that China's National Medical Products Administration has accepted a new drug application for bepirovirsen, its investigational treatment for chronic hepatitis B. This submission is supported by positive Phase III clinical trial results showing statistically significant functional cure rates. The drug aims to address the significant health burden of chronic hepatitis B, which affects millions in China and worldwide.", "sentiment_score": 0.236944, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.609525, "sentiment": { "label": "positive", "score": 0.273, "confidence": 0.27 } }, { "source": "alpha_vantage", "title": "Wealth Enhancement Advisory Services LLC Purchases 9,480 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-wealth-enhancement-advisory-services-llc-purchases-9480-shares-of-iqvia-holdings-inc-iqv-2026-03-28/", "date": "2026-03-28", "summary": "Wealth Enhancement Advisory Services LLC has increased its stake in IQVIA Holdings Inc. by 35.8%, acquiring an additional 9,480 shares and bringing its total holdings to 35,960 shares valued at $8.674 million. IQVIA currently holds a consensus \"Buy\" rating with a price target of $229.13 and recently surpassed quarterly earnings expectations. The company also issued a positive FY2026 EPS guidance of $12.55–$12.85.", "sentiment_score": 0.469581, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "Eagle Rock Investment Company LLC Buys 14,084 Shares of IQVIA Holdings Inc. $IQV", "url": "https://www.marketbeat.com/instant-alerts/filing-eagle-rock-investment-company-llc-buys-14084-shares-of-iqvia-holdings-inc-iqv-2026-03-28/", "date": "2026-03-28", "summary": "Eagle Rock Investment Company LLC increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 30.4% in the fourth quarter, acquiring an additional 14,084 shares and bringing their total holdings to 60,416 shares valued at $13.62 million. Other institutional investors also adjusted their positions in IQV. Several Wall Street analysts have issued \"Buy\" or \"Overweight\" ratings for IQVIA, with an average price target of $229.13.", "sentiment_score": 0.395417, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } } ] } }